Sleep Research Society

Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials

BACKGROUND: Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin receptor 2-selective agonist, reduced symptoms of narcolepsy type 1 in...

22 Quality of life and services use in patients diagnosed with brain tumours: data from a national cancer survivorship study

Abstract Introduction About 13,000 new patients are diagnosed annually with a primary brain tumour in the UK and less than 20% of patients survive 10 years post-diagnosis. Patient-Reported Outcomes and Experiences (PROMs & PREMs) are largely used in clinical trials that recruit f...